Pliant Therapeutics Inc (PLRX)
13.44
-0.38
(-2.71%)
USD |
NASDAQ |
May 08, 16:00
13.47
+0.02
(+0.19%)
After-Hours: 20:00
Pliant Therapeutics Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 0.248M |
| March 31, 2023 | 1.332M |
| December 31, 2022 | 1.965M |
| September 30, 2022 | 1.482M |
| June 30, 2022 | 4.989M |
| March 31, 2022 | 1.249M |
| December 31, 2021 | 1.999M |
| September 30, 2021 | 1.61M |
| Date | Value |
|---|---|
| June 30, 2021 | 1.789M |
| March 31, 2021 | 2.174M |
| December 31, 2020 | 4.465M |
| September 30, 2020 | 4.814M |
| June 30, 2020 | 3.60M |
| March 31, 2020 | 28.94M |
| December 31, 2019 | 57.05M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.248M
Minimum
Jun 2023
57.05M
Maximum
Dec 2019
7.847M
Average
1.999M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Masimo Corp | 548.90M |
| Liquidia Corp | 4.531M |
| Vor Biopharma Inc | -- |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.065M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -46.96M |
| Total Expenses (Quarterly) | 52.39M |
| EPS Diluted (Quarterly) | -0.78 |
| Enterprise Value | 381.32M |
| Earnings Yield | -21.35% |
| Normalized Earnings Yield | -20.38 |